Author(s): Doolittle GC, Simpson KM, Lindsley HB, Doolittle GC, Simpson KM, Lindsley HB
Abstract Share this page
Abstract A patient with rheumatoid arthritis presented with pancytopenia 3 weeks after initiation of low-dose methotrexate administered orally. She had minimal renal insufficiency and hypoalbuminemia prior to initiation of methotrexate therapy, and had received a nonsteroidal anti-inflammatory drug concurrently. Bone marrow recovery occurred within 3 weeks. Patients receiving low-dose methotrexate therapy for rheumatoid arthritis require early monitoring for bone marrow injury, especially those who have risk factors for possible methotrexate toxicity.
This article was published in Arch Intern Med
and referenced in Journal of Drug Metabolism & Toxicology